Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 6/20 | 0.52 |
| ▸ | MMP2 | P08253 | 5/20 | 0.52 |
| ▸ | MMP9 | P14780 | 5/20 | 0.52 |
| ▸ | MMP8 | P22894 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266880 | 0.90 | HRH3 (0.61) | HRH3HPGDSMN1; SMN2USP2TSHR | |
| SCHEMBL13244713 | 0.78 | MMP2 (0.47) | HRH3MMP13MMP2MMP8 | |
| SCHEMBL255145 | 0.77 | MMP13 (0.57) | HPGDMMP13MMP2MMP9MMP8 | |
| SCHEMBL1014002 | 0.77 | HPGD (0.86) | HRH3HPGDSMN1; SMN2USP2TSHR | |
| SCHEMBL27805648 | 0.76 | MMP13 (0.56) | HRH3HPGDMMP13MMP2MMP9 | |
| SCHEMBL15382483 | 0.76 | MMP2 (0.49) | HRH3MMP13MMP2MMP9MMP8 | |
| SCHEMBL13244710 | 0.75 | KDM4E (0.63) | MMP13MMP2MMP9MMP8SMN1; SMN2 | |
| SCHEMBL1450838 | 0.75 | HRH3 (0.78) | HRH3HPGDSMN1; SMN2USP2TSHR | |
| SCHEMBL13636330 | 0.74 | HRH3 (1.00) | HRH3HPGDSMN1; SMN2USP2TSHR | |
| SCHEMBL3456205 | 0.73 | HPGD (1.00) | HRH3HPGDSMN1; SMN2USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617256-B2 | Antibacterial agents | ACHAOGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2170814-B1 | ANTIBACTERIAL AGENTS | ACHAOGEN INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | HRH3 4192/4885HPGD 307/4885MMP13 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.